View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, Feb. 13 (HealthDay News) -- Postoperative radiation therapy (PORT) is not associated with improved survival for elderly patients with N2 non-small-cell lung cancer (NSCLC), according to a study published online Feb. 13 in Cancer.
Juan P. Wisnivesky, M.D., Dr.Ph., of the Mount Sinai School of Medicine in New York City, and colleagues used data from the Surveillance, Epidemiology, and End Results (SEER) registry linked to Medicare records to identify 1,307 patients who had stage III NSCLC with N2 lymph node involvement, diagnosed between 1992 and 2005. Survival of patients who did and did not receive PORT was compared used propensity scoring methods and instrumental variable analysis.
The researchers found that 710 patients (54 percent) were treated with PORT. PORT was not associated with improved survival in patients with N2 disease (hazard ratio, 1.11; 95 percent confidence interval, 0.97 to 1.27), based on propensity score analysis. Similar results were seen on restricting analyses to patients who did or did not receive chemotherapy and patients who received intermediate-complexity or high-complexity radiotherapy. Additionally, similar results were found when analyses were repeated adjusting for time trends in the use of other lung cancer treatments. The absolute improvement in one-year and three-year survival with PORT was −0.04 and −0.08, respectively, based on the instrumental variable estimator.
"The current data suggested that PORT is not associated with improved survival for elderly patients with N2 disease. These findings have important clinical implications, because SEER data indicate that a large percentage of elderly patients currently receive PORT despite the lack of definitive evidence about its effectiveness," the authors write.
One author disclosed financial ties to pharmaceutical companies.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top